The S.E.C.’s Federal Securities Law Investigation of Flu Vaccine Manufacturer Chiron
On October 13, 2004, Chiron disclosed that it received a notice from the U.S. Securities and Exchange Commission
“to determine whether certain provisions of the federal securities laws have been violated by Chiron.”
Chiron’s General Counsel announced that the FDA was interested in “materials relating to Fluvirin®,” and the the U.K. health regulatory agency’s suspension of Fluviron® flu vaccine production at the company’s Liverpool, England plant.
Below is the text of Chiron’s disclosure about the federal securities law investigation launched by authorities:
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported): October 13, 2004
Chiron Corporation
(Exact name of registrant as specified in its charter)
|
Delaware
|
|
0-12798
|
|
94-2754624
|
|
(State or other
jurisdiction of
incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
4560
Horton Street, Emeryville, CA
|
|
94608
|
|
(Address of
principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone
number, including area code (510) 655-8730
N/A
(Former name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement communications pursuant to
Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to
Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01.
Other Events.
On
October 13, 2004, Chiron Corporation received a notice from the Securities and Exchange Commission (“SEC”)
that it has opened an informal inquiry to determine whether certain provisions
of the federal securities laws have been violated by Chiron. The SEC has requested that Chiron voluntarily
provide certain documents and materials, including materials relating to
Fluvirin® and the suspension by
the United Kingdom’s Medicines and Healthcare products Regulatory Agency of
Chiron’s license to manufacture the Fluvirin vaccine.
Chiron intends to fully
cooperate with the SEC in its informal inquiry.
# # #
2
SIGNATURE
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
|
|
CHIRON CORPORATION
|
|
|
|
(Registrant)
|
|
|
|
|
|
|
|
|
|
|
|
|
Date: October 13, 2004
|
By:
|
/s/ Ursula
B. Bartels
|
|
|
|
|
Ursula B. Bartels
|
|
|
|
|
Vice President and
General Counsel
|
|
|
|
|
|
3
| 
